ECE2019 Poster Presentations Diabetes, Obesity and Metabolism 2 (100 abstracts)
Real-world experience of generalized and partial lipodystrophy patients enrolled in the metreleptin early access program
Keziah Cook 1 , Anna Stears 2 , David Araujo-Vilar 3 , Ferruccio Santini 4 , Stephen O’Rahilly 2 , Giovanni Ceccarini 4 , Shruti Tibrewala 1 , Pamela Bradt 5 , Corinne Vigouroux 6 , Camille Vatier 6 & David B Savage 2
1Analysis Group, Menlo Park, CA, USA; 2University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Cambridge, UK; 3University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain; 4University Hospital of Pisa, Pisa, Italy; 5Aegerion Pharmaceuticals, Cambridge, MA, USA; 6Sorbonne University, Reference Center of Rare Diseases PRISIS, Hospital Saint-Antoine, Paris, France.
Objective: To evaluate the real-world experience of patients with generalized (GL) and partial (PL) lipodystrophy initiating treatment with metreleptin as part of an early access program (EAP).
Methods: A retrospective data collection was conducted from four countries for patients enrolled in the EAP. A descriptive analysis was performed on selected patient characteristics, baseline organ impairments and complications, and response to metreleptin therapy, measured through changes in triglycerides (TG) and HbA1c.
Results: 53 lipodystrophy patients (GL, PL: 28, 25) were identified in four countries (France: 19, Italy: 3, Spain: 11, UK: 20). Average age at metreleptin initiation for GL and PL patients was 17.4 (SD: 14.9) and 38.6 (SD: 12.6) respectively. Among patients treated in France, Italy, and UK, 100% presented with organ impairments at baseline, including liver impairment (GL, PL: 100%, 100%), cardiovascular damage (24%, 44%), kidney impairment (35%, 20%) and pancreatitis (12%, 16%). 93% of patients had diabetes. Prior to treatment, 95% of GL patients and 71% of PL patients had TG >200 mg/dl and 78% of GL patients and 68% of PL patients had HbA1c >7%. Duration of patients’ metreleptin exposure varied, with a maximum of 14.7 years (mean 5.4, S.D.: 3.5). Following treatment for GL patients, mean % TG change was a decrease of 53% (P<0.001) and mean HbA1c change was a 1.9 percentage point decrease (P<0.001) between baseline and 12 months. By month 12, 50% of GL patients (vs 5% at baseline) achieved TG ≤200 mg/dl and 57% of patients (vs 22% at baseline) achieved HbA1c ≤7%. For PL patients, mean % TG change was a decrease of 21.5% (P<0.005) and mean HbA1c change was a 0.5 percentage point decrease (P<0.1). By month 12, 52% of PL patients (vs 29% at baseline) achieved TG ≤200 mg/dl with no change in the 32% at baseline that achieved HbA1c ≤7%. No new safety signals emerged as EAP data were integrated with existing safety data. In the clinical trial, the most frequent adverse reactions reported included decreased weight (17%) and mild occurrences of hypoglycaemia (14%); other adverse reactions affected <10%.
Conclusions: Response to metreleptin in real-world EAP patients was consistent with clinical trial experience for registration, which resulted in mean % TG decrease (GL, PL: 32.1, 37.4) and HbA1c percentage point decrease (GL, PL: 2.2, 0.9). Ongoing research is needed to further characterize the burden of lipodystrophy on patients and the impact of metreleptin.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more